Genertec Universal Medical reported steady first-quarter performance for the period ended 31 March 2026. Revenue fell 4.50% year-on-year, mainly because of lower finance business income, yet profit for the period increased 5.20% after tighter funding-cost control and lower healthcare business expenses. Profit attributable to ordinary shareholders rose 4.80%.
Integrated healthcare operations remained the growth engine. New clinical accreditations lifted the Group’s provincial-level key specialties to 26. Outpatient and emergency visits climbed 4.50% as extended-hour and non-stop clinics expanded. Health check-up revenue surged 13.30%, reinforcing the non-insurance income base. Operational efficiencies improved: average length of stay shortened to 8.9 days and output per bed advanced 2.70%; pharmaceutical and consumables cost ratio fell 1.30 percentage points while labour cost ratio declined 3.20 points.
Specialised care and healthcare technology advanced through both organic build-out and M&A. Key milestones included: opening of Genertec Universal Ophthalmology Beijing Flagship Hospital (20 beds, 47 top-tier devices); completion of Mainland China’s first Histotripsy liver-cancer treatment alongside the launch of the “Non-Invasive Hai Sheng Plan”; release of the industry’s first Medical Equipment Lifecycle Service Specification; and a win for the “Smart Haidian” digital-health platform covering two tertiary hospitals in Beijing.
Finance operations focused on medical health, elder care and equipment manufacturing. The segment pursued integrated models such as “finance lease + life-cycle equipment management” and closed Tianjin’s first RMB 500 million ESG-linked syndicated loan. Net interest margin and spread stayed level with the prior-year period, while asset quality and provision coverage remained stable.
Management emphasised that these figures are unaudited internal data; investors should exercise caution when dealing in the Company’s securities.
Comments